基于肿瘤亚区演变的影像特征评估口咽癌早期反应与预后
本研究回顾性分析162例接受同步放化疗的口咽鳞癌患者,利用18F-FDG PET和增强CT将原发肿瘤及受累淋巴结空间分割为亚区,提取基线至治疗中期的亚区体积变化特征,构建影像特征预测无进展生存期。该特征在训练和验证队列中均优于传统影像指标,并可独立于分期、HPV状态和吸烟史分层高风险与低风险患者。
要点
- 基于18F-FDG PET和增强CT识别的3个肿瘤内亚区演变特征可预测口咽癌无进展生存期。
- 影像特征预测无进展生存期的C-index在训练队列为0.72 vs 0.67,验证队列为0.66 vs 0.56。
- 影像特征分层高风险与低风险组2年无进展生存率在训练队列为59.1% vs 89.4%,验证队列为61.4% vs 87.8%。
核心结论
- 所提出的影像特征能更准确预测口咽鳞癌疾病进展,若经前瞻性验证,可能优化风险适应性治疗的患者选择。
研究设计与样本
- 回顾性分析162例接受同步放化疗的口咽鳞癌患者,等分为训练和验证队列,临床特征相似。
- 采用稳健共识聚类方法基于18F-FDG PET和增强CT将原发肿瘤及受累淋巴结空间分割为亚区。
- 提出量化影像特征表征基线与治疗中期之间亚区及瘤周/淋巴结组织的体积变化,并评估可重复性。
- 通过L1正则化Cox回归模型构建预测无进展生存期的影像特征。
主要发现
- 识别出3个表型不同的肿瘤内亚区:代谢活跃且异质性、强化且异质性、代谢不活跃且均质性。
- 最终Cox模型包含4个基于亚区演变的特征。
- 影像特征预测无进展生存期的C-index在训练队列为0.72 vs 0.67,验证队列为0.66 vs 0.56,优于治疗中期代谢肿瘤体积等传统影像指标。
- 影像特征将患者分为高风险与低风险组,2年无进展生存率在训练队列为59.1% vs 89.4%(风险比4.4;95%CI 1.4-13.4),验证队列为61.4% vs 87.8%(风险比4.6;95%CI 1.7-12.1)。
- 调整分期、人乳头瘤病毒状态和吸烟史后,影像特征仍是无进展生存期的独立预测因子。
临床怎么用
- 基于基线和治疗中期18F-FDG PET及增强CT提取的亚区演变特征,可用于口咽鳞癌患者进展风险分层。
- 该影像特征可能辅助筛选适合风险适应性治疗(如降低治疗强度)的口咽鳞癌患者,但需前瞻性验证。
局限性
- 研究为回顾性分析,影像特征需前瞻性验证后才能用于临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has been rapidly increasing. Disease stage and smoking history are often used in current clinical trials to select patients for deintensification therapy, but these features lack sufficient accuracy for predicting disease relapse. Our purpose was to develop an imaging signature to assess early response and predict outcomes of OPSCC. Methods: We retrospectively analyzed 162 OPSCC patients treated with concurrent chemoradiotherapy, equally divided into separate training and validation cohorts with similar clinical characteristics. A robust consensus clustering approach was used to spatially partition the primary tumor and involved lymph nodes into subregions (i.e., habitats) based on 18F-FDG PET and contrast CT imaging. We proposed quantitative image features to characterize the temporal volumetric change of the habitats and peritumoral/nodal tissue between baseline and midtreatment. The reproducibility of these features was evaluated. We developed an imaging signature to predict progression-free survival (PFS) by fitting an L1-regularized Cox regression model. Results: We identified 3 phenotypically distinct intratumoral habitats: metabolically active and heterogeneous, enhancing and heterogeneous, and metabolically inactive and homogeneous. The final Cox model consisted of 4 habitat evolution-based features. In both cohorts, this imaging signature significantly outperformed traditional imaging metrics, including midtreatment metabolic tumor volume for predicting PFS, with a C-index of 0.72 versus 0.67 (training) and 0.66 versus 0.56 (validation). The imaging signature stratified patients into high-risk versus low-risk groups with 2-y PFS rates of 59.1% versus 89.4% (hazard ratio, 4.4; 95% confidence interval, 1.4-13.4 [training]) and 61.4% versus 87.8% (hazard ratio, 4.6; 95% confidence interval, 1.7-12.1 [validation]). The imaging signature remained an independent predictor of PFS in multivariable analysis adjusting for stage, human papillomavirus status, and smoking history. Conclusion: The proposed imaging signature allows more accurate prediction of disease progression and, if prospectively validated, may refine OPSCC patient selection for risk-adaptive therapy.
引用
- Wu J, Gensheimer MF, Zhang N, et al. Tumor Subregion Evolution-Based Imaging Features to Assess Early Response and Predict Prognosis in Oropharyngeal Cancer. J Nucl Med. 2019. PMID: 31420498. doi:10.2967/jnumed.119.230037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。